<DOC>
	<DOCNO>NCT02316964</DOCNO>
	<brief_summary>This pilot trial study decitabine , donor natural killer cell , aldesleukin treat patient acute myeloid leukemia come back previous treatment ( relapse ) respond previous treatment ( refractory ) . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving donor natural killer cell decitabine may boost patient 's immune system help see remain cancer cell belong patient 's body cause destroy ( call graft-versus-tumor effect ) . Aldesleukin may stimulate natural killer cell kill acute myeloid leukemia cell . Giving decitabine , donor natural killer cell , aldesleukin may better treatment acute myeloid leukemia .</brief_summary>
	<brief_title>Decitabine , Donor Natural Killer Cells , Aldesleukin Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility safety decitabine follow natural killer ( NK ) cell IL-2 ( Interleukin ) . II . To define specific toxicity dose limit toxicity ( DLT ) decitabine plus NK cell IL-2 . III . To determine feasibility safety manufacturing process NK cell . SECONDARY OBJECTIVES : I . To determine overall response rate ( ORR ) . II . To determine rate complete remission ( CR ) regimen decitabine plus NK cell IL-2 ( interleukin ) acute myeloid leukemia ( AML ) . TERTIARY OBJECTIVES : I . To correlate biological activity decitabine upregulating ligand mediate susceptibility NK mediate cytotoxicity . II . To characterize biological activity infuse NK cell persistence define NK chimerism . III . To evaluate decitabine immunosuppressive property modulate change endogenous cytokine patient . OUTLINE : Patients receive decitabine intravenously ( IV ) 60 minute day -4 0 undergo infusion allogeneic NK cell day 0 . Beginning 1 hour infusion allogeneic NK cell , patient also receive aldesleukin subcutaneously ( SC ) every day 6 dos . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients relapse refractory AML Patients without response two cycle decitabine Patients primary refractory AML ( persistent disease standard induction 7+3 ) relapse AML Patients relapse postallogeneic transplant Patients secondary AML therapy related disease ( tAML ) eligible ; patient receive decitabine 5azacytidine prior treatment myelodysplastic syndrome ( MDS ) remain eligible Patients central nervous system ( CNS ) leukemia eligible long receive treatment recent cerebrospinal fluid ( CSF ) analysis negative leukemia If patient comorbid medical illness , life expectancy attribute comorbid illness must great 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Total bilirubin &lt; 2.0 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2.5 X institutional upper limit normal Creatinine &lt; 2.0 mg/dL New York Heart Association ( NYHA ) congestive heart failure ( CHF ) class II good Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; patient agree , patient eligible ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Human immunodeficiency virus ( HIV ) infection without acquire immune deficiency syndrome ( AIDS ) define criterion eligible DONOR : Donors must human leukocyte antigen ( HLA ) haploidentical firstdegree relative patient ; eligible donor include biological parent , sibling halfsiblings , child DONOR : Donor must general good health eligible apheresis determine medical provider DONOR : HLAhaploidentical donor/recipient match least class I serologic type HLAA B locus DONOR : Willing able provide inform consent Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study Patients receive investigational agent patient receive investigational agent within 14 day enrollment Patients history allergic reaction attribute compound similar chemical biologic composition decitabine easily manage Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; infection common feature AML , patient active infection permit enroll provide infection control Patients serious medical psychiatric illness likely interfere participation clinical study Pregnant woman woman breastfeed exclude study ; confirmation subject pregnant must establish negative serum Bhuman chorionic gonadotropin ( BhCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilized woman Patients metastatic malignant solid tumor receive treatment past 6 month exclude DONOR : Pregnancy DONOR : HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>decitabine</keyword>
</DOC>